MindMed Ready To Take LSD Therapy Into Phase III For Anxiety

Treatment Infrastructure In Place Due To J&J’s Spravato

 
• By Mandy Jackson

Mind Medicine’s LSD product MM120 will move into Phase III in the second half of 2024 after it showed efficacy in generalized anxiety disorder out to 12 weeks with a single administration in Phase IIb. 

Depression and anxiety concept of woman in fetal position on the sofa with gloomy colors
Half of anxiety patients seeking treatment do not respond to first-line drugs • Source: Shutterstock

More from Clinical Trials

More from R&D